Senate Bill 351 Alabama 2026 Session

Summary

Primary Sponsor

April WeaverSenator

Republican

Session

2026 Regular Session

Title

Public health, authorized forms of single-dose epinephrine used by public schools and authorized entities expanded

Summary

SB351 expands the forms of single-dose epinephrine usable in schools and by authorized entities and adds an on-campus preparedness and liability framework.

What This Bill Does

It allows any FDA-approved single-dose premeasured epinephrine delivery system to be carried by students and stocked or administered by schools, authorized entities, and certain staff for life-threatening allergic reactions. It requires public K-12 schools to implement an anaphylaxis preparedness program with on-campus supplies, proper storage, and emergency response procedures. It creates liability protections for schools, trained personnel, physicians, pharmacists, and entities acting in good faith under this act, while allowing prescriptions for epinephrine auto-injectors to be issued to authorized entities with two-year validity. It authorizes authorized entities outside schools (such as camps, colleges, day cares, youth leagues, etc.) to stock, provide, prescribe, and dispense epinephrine auto-injector delivery systems, and it requires training, incident reporting to the Department of Public Health, and annual summaries, with the campus supply requirement dependent on state funding and the act taking effect on October 1, 2026.

Who It Affects

• Students and school staff (nurses and trained personnel) at public and nonpublic K-12 schools, who may carry/self-administer epinephrine and rely on on-campus supplies and training.
• Authorized entities outside schools (e.g., recreation camps, colleges/universities, day cares, youth leagues, workplaces) and health professionals (prescribers/pharmacists) who stock, dispense, or administer epinephrine auto-injector systems and provide related training and incident reporting.

Key Provisions

• Expands approved forms to FDA-approved single-dose premeasured epinephrine delivery systems beyond traditional auto-injectors.
• Requires anaphylaxis preparedness programs in public K-12 schools with on-campus supplies, storage standards, staff training, and emergency response procedures.
• Provides immunity from civil liability for schools, trained personnel, and providers acting under this act, with exceptions for willful misconduct; physicians and pharmacists are protected when acting within their roles and the act aligns with existing medical liability law.
• Allows authorized entities outside schools to acquire, stock, prescribe, and dispense epinephrine auto-injector delivery systems for use in emergencies; prescriptions to authorized entities are valid for two years; storage, accessibility, and training requirements are specified.
• Requires incident reporting to the Department of Public Health and annual summaries of reports; funding is required for maintaining campus supplies; effective date is October 1, 2026.
• Defines key terms (e.g., epinephrine auto-injector delivery system, authorized entity, medical practitioner) to clarify how the new provisions work.

AI-generated summary using openai/gpt-5-nano-2025-08-07 on Mar 10, 2026. May contain errors — refer to the official bill text for accuracy.

Subjects

Health